Skip to main content
BCAB
NASDAQ Life Sciences

BioAtla Creates Super-Voting Share for CEO to Force Reverse Stock Split After Failed Shareholder Vote

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
9
Price
$0.363
Mkt Cap
$18.578M
52W Low
$0.24
52W High
$1.43
Market data snapshot near publication time

summarizeSummary

BioAtla, Inc. has created and issued a Super-Voting Series A Junior Preferred Stock to its CEO, granting him the power to ensure the approval of a reverse stock split, following the repeated failure to secure the necessary shareholder votes.


check_boxKey Events

  • Super-Voting Share Issued to CEO

    BioAtla issued one Series A Junior Preferred Stock (Super-Voting Share) to its Chairman, CEO, and co-founder, Jay M. Short, Ph.D., for a purchase price of $0.01.

  • Significant Governance Change

    The Super-Voting Share grants the holder voting power equal to the total number of common shares outstanding on specific proposals, including a reverse stock split. The holder is required to vote 'for' the proposal if at least two-thirds of the common stock present and entitled to vote approve it.

  • Reverse Stock Split Vote Failed Repeatedly

    Shareholders failed to approve a reverse stock split proposal at both the originally convened and reconvened special meetings, despite over 70% of proxies received voting 'FOR' it, due to insufficient total votes.

  • Meeting Adjourned to Force Vote

    The special meeting was adjourned again to January 26, 2026, explicitly to allow the Super-Voting Share to be utilized to ensure the approval of the Reverse Stock Split Proposal.


auto_awesomeAnalysis

This filing reveals BioAtla's desperate measures to effect a reverse stock split, likely to maintain its Nasdaq listing. By issuing a single "Super-Voting Share" to the CEO for a nominal fee, the company has effectively bypassed direct shareholder dissent. This share's voting power is tied to the total outstanding common stock and is designed to ensure the reverse split passes if at least two-thirds of *present* common shareholders vote in favor. This move raises significant corporate governance concerns, as it concentrates voting power in the CEO's hands to override the collective will of shareholders on a critical matter. Investors should view this as a strong signal of financial distress and a potential threat to minority shareholder rights.

At the time of this filing, BCAB was trading at $0.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.6M. The 52-week trading range was $0.24 to $1.43. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed BCAB - Latest Insights

BCAB
Apr 02, 2026, 4:13 PM EDT
Source: Wiseek News
Importance Score:
8
BCAB
Apr 02, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
8
BCAB
Mar 31, 2026, 4:05 PM EDT
Filing Type: 10-K
Importance Score:
10
BCAB
Mar 31, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
BCAB
Mar 23, 2026, 4:04 PM EDT
Filing Type: 8-K
Importance Score:
9
BCAB
Mar 02, 2026, 7:42 AM EST
Filing Type: DEFA14A
Importance Score:
8
BCAB
Mar 02, 2026, 7:41 AM EST
Filing Type: 8-K
Importance Score:
9
BCAB
Feb 09, 2026, 6:01 AM EST
Filing Type: 8-K
Importance Score:
8
BCAB
Feb 06, 2026, 5:02 PM EST
Filing Type: 8-K
Importance Score:
9
BCAB
Jan 30, 2026, 5:13 PM EST
Filing Type: PREM14A
Importance Score:
9